Celanese Highlights Safe and Effective Drug Delivery Applications of EVA

Celanese Corporation highlighted innovative drug delivery applications of ethylene vinyl acetate (EVA) at CPhI.

Celanese shared technical and application-specific information with customers and conference attendees about its broad medical portfolio, specifically highlighting the company’s VitalDose EVA product in emerging pharmaceutical drug delivery applications, including implants for treatment of eye disease, retroviral infection, addiction, and other novel applications.

“Controlled-release drug delivery has always presented considerable challenges to developers and formulators, such as drug loading, device size, and long-term sustained drug release,” said Susan Rahe, global business director of the Celanese EVA polymers business. “VitalDose EVA offers a safe and effective controlled release solution and is an inert thermoplastic that is expanding design possibilities for our customers with its customizable drug release properties.”

VitalDose EVA as a controlled release excipient is developed for a wide variety of pharmaceutical products with varying routes of administration, including ophthalmic, intraoral, intravaginal, subcutaneous and transdermal. Celanese demonstrated how VitalDose EVA can be used as a safe and reliable controlled release excipient to solve fundamental drug delivery problems including patient compliance and frequency of dosage.